FT Options’s Regulus Therapeutics RGLS Stock Holding History

FT Options’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-42	Closed	-$14K	–	441
2016 Q2	$14K	Buy	+42	New	+$30.1K	0.01%	274

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FT Options's RGLS Position: Q3 2016 in Review

FT Options sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 42 shares — an estimated $14K sold.

FT Options first reported a position in RGLS in Q2 2016 and held it in 1 quarter. The position peaked at $14K in Q2 2016. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

FT Options reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
FT Options sold 42 Regulus Therapeutics shares in Q3 2016, an estimated $14K.
FT Options first reported a position in Regulus Therapeutics in Q2 2016 and held it in 1 quarter.
FT Options's Regulus Therapeutics position peaked at $14K in Q2 2016.
83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.